44P - The identification of circulating micro-RNAs (miRNA) to monitor tumour burden (tb) in small cell lung cancer (SCLC)
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Small-Cell Lung Cancer
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A. Greystoke1, M. Ayub2, N. Smith1, C. Hodgkinson1, D. Morris1, R. Metcalf1, L. Carter1, F. Blackhall3, C. Dive1, G. Brady1
SCLC is characterized by high metastatic burden, poor prognosis and emergence of treatment resistance. Sensitive circulating biomarkers of TB have potential to inform on progression prior to onset of symptoms, to aid in identifying novel treatment targets and as pharmacodynamic biomarkers in early clinical trials. We evaluated miRNA profiling of plasma from SCLC patients in order to identify potential biomarkers of TB. Using explants derived from patient circulating tumour cells (CTCs) we evaluated the relationship between levels of identified miRNA in the circulation and TB.